ABSTRACT
Dalbavancin (Dalvance, Xydalba) is a semisynthetic lipoglycopeptide approved in 2014 by the US Food and Drug Administration (FDA) and in 2015 by the European Medicines Agency for acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible Gram-positive isolates in adults. Although originally approved for a two-dose regimen, the compound has an extended half-life (t 1/2) that enables single-dose therapy for ABSSSIs (Dunne et al., 2016a; Dunne et al., 2016b). Dalbavancin has potent in vitro activity against most Gram-positive organisms with lower minimum inhibitory concentration (MIC) values than vancomycin and other investigational lipoglycopeptides (i.e. oritavancin, telavancin). It is also active against drug-resistant pathogens of concern such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), except for strains exhibiting vanA resistance.
